

Rubius Therapeutics Logo

## Rubius Therapeutics to Participate in the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology

September 20, 2018

CAMBRIDGE, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, announced today that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology on Tuesday, October 2, 2018, at 9:00 a.m. ET.

A live audio webcast will be available within the [Investor and News](#) section of the Rubius Therapeutics' website. An archived replay will be accessible for 90 days following the event.

### About Rubius Therapeutics

Rubius Therapeutics is a biopharmaceutical company pioneering the development of a new class of medicines called Red Cell Therapeutics™. The Company's proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius' initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit [www.rubiustx.com](http://www.rubiustx.com) or follow us on [Twitter](#).

### Media Contact:

Dan Budwick  
1AB, Inc.  
+1 (973) 271-6085  
[dan@1abmedia.com](mailto:dan@1abmedia.com)

### Investor Contact:

Lori Melançon  
Vice President, Corporate Communications and Investor Relations  
+1 (617) 229-6122  
[lori.melancon@rubiustx.com](mailto:lori.melancon@rubiustx.com)



Source: Rubius Therapeutics